Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zerlasiran (SLN360) in Participants With Elevated Lipoprotein(a) at High Risk of ASCVD Events
NCT05537571Phase 2Completed
- Sponsor
- Silence Therapeutics
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 7
01
Overview
A Phase 2 trial of zerlasiran in atherosclerotic cardiovascular disease (ASCVD), Hyperlipoproteinemia a, sponsored by Silence Therapeutics. Started Dec 2022; status: completed.
02
Drugs
zerlasiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT05537571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537571.